113 related articles for article (PubMed ID: 21152880)
1. Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma.
De la Cruz-Hernández E; Perez-Plasencia C; Pérez-Cardenas E; Gonzalez-Fierro A; Trejo-Becerril C; Chávez-Blanco A; Taja-Chayeb L; Vidal S; Gutiérrez O; Dominguez GI; Trujillo JE; Duenas-González A
Oncol Rep; 2011 Feb; 25(2):399-407. PubMed ID: 21152880
[TBL] [Abstract][Full Text] [Related]
2. The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study.
de la Cruz-Hernández E; Pérez-Cárdenas E; Contreras-Paredes A; Cantú D; Mohar A; Lizano M; Dueñas-González A
Virol J; 2007 Feb; 4():18. PubMed ID: 17324262
[TBL] [Abstract][Full Text] [Related]
3. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.
Arce C; Pérez-Plasencia C; González-Fierro A; de la Cruz-Hernández E; Revilla-Vázquez A; Chávez-Blanco A; Trejo-Becerril C; Pérez-Cárdenas E; Taja-Chayeb L; Bargallo E; Villarreal P; Ramírez T; Vela T; Candelaria M; Camargo MF; Robles E; Dueñas-González A
PLoS One; 2006 Dec; 1(1):e98. PubMed ID: 17183730
[TBL] [Abstract][Full Text] [Related]
4. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
Dueñas-Gonzalez A; Coronel J; Cetina L; González-Fierro A; Chavez-Blanco A; Taja-Chayeb L
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1433-44. PubMed ID: 25154405
[TBL] [Abstract][Full Text] [Related]
5. Epigenome: a new target in cancer therapy.
Giacinti L; Vici P; Lopez M
Clin Ter; 2008; 159(5):347-60. PubMed ID: 18998037
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
7. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.
Duenas-Gonzalez A; Candelaria M; Perez-Plascencia C; Perez-Cardenas E; de la Cruz-Hernandez E; Herrera LA
Cancer Treat Rev; 2008 May; 34(3):206-22. PubMed ID: 18226465
[TBL] [Abstract][Full Text] [Related]
8. Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression.
Song Y; Zhang C
Cancer Chemother Pharmacol; 2009 Mar; 63(4):605-13. PubMed ID: 18521605
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
11. Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate.
Mani E; Medina LA; Isaac-Olivé K; Dueñas-González A
Eur J Gynaecol Oncol; 2014; 35(2):140-2. PubMed ID: 24772915
[TBL] [Abstract][Full Text] [Related]
12. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes.
Milutinovic S; D'Alessio AC; Detich N; Szyf M
Carcinogenesis; 2007 Mar; 28(3):560-71. PubMed ID: 17012225
[TBL] [Abstract][Full Text] [Related]
13. Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model.
Feng D; Wu J; Tian Y; Zhou H; Zhou Y; Hu W; Zhao W; Wei H; Ling B; Ma C
PLoS One; 2013; 8(11):e80657. PubMed ID: 24260446
[TBL] [Abstract][Full Text] [Related]
14. New approaches to pathogenic gene function discovery with human squamous cell cervical carcinoma by gene ontology.
Seo MJ; Bae SM; Kim YW; Kim YW; Hur SY; Ro DY; Lee JM; Namkoong SE; Kim CK; Ahn WS
Gynecol Oncol; 2005 Mar; 96(3):621-9. PubMed ID: 15721403
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes.
Zambrano P; Segura-Pacheco B; Perez-Cardenas E; Cetina L; Revilla-Vazquez A; Taja-Chayeb L; Chavez-Blanco A; Angeles E; Cabrera G; Sandoval K; Trejo-Becerril C; Chanona-Vilchis J; Duenas-González A
BMC Cancer; 2005 Apr; 5():44. PubMed ID: 15862127
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic alterations and cancer: new targets for therapy.
Allen A
IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
[TBL] [Abstract][Full Text] [Related]
17. D-Serine exposure resulted in gene expression changes indicative of activation of fibrogenic pathways and down-regulation of energy metabolism and oxidative stress response.
Soto A; DelRaso NJ; Schlager JJ; Chan VT
Toxicology; 2008 Jan; 243(1-2):177-92. PubMed ID: 18061331
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
Candelaria M; Gallardo-Rincón D; Arce C; Cetina L; Aguilar-Ponce JL; Arrieta O; González-Fierro A; Chávez-Blanco A; de la Cruz-Hernández E; Camargo MF; Trejo-Becerril C; Pérez-Cárdenas E; Pérez-Plasencia C; Taja-Chayeb L; Wegman-Ostrosky T; Revilla-Vazquez A; Dueñas-González A
Ann Oncol; 2007 Sep; 18(9):1529-38. PubMed ID: 17761710
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
Li LC; Carroll PR; Dahiya R
J Natl Cancer Inst; 2005 Jan; 97(2):103-15. PubMed ID: 15657340
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line.
Valentini A; Biancolella M; Amati F; Gravina P; Miano R; Chillemi G; Farcomeni A; Bueno S; Vespasiani G; Desideri A; Federici G; Novelli G; Bernardini S
Drug Metab Dispos; 2007 Jun; 35(6):968-72. PubMed ID: 17371798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]